email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Mini Review(ISSN: 2638-5945)

Aspirin, Vascular Disease and Cancer: 50 Years of Controversy and the Jury’s Still Out!

Volume 1 - Issue 5

Peter Elwood*

  • Author Information Open or Close
    • Department of Inst of Population Medicine, Cardiff University, UK

    *Corresponding author: Peter Elwood, Department of Inst of Population Medicine, Cardiff University, UK

Received: May 26, 2018;   Published: June 11, 2018

DOI: 10.32474/OAJOM.2018.02.000126

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The story of aspirin and vascular disease starts with John O Brien, a haematologist in Portsmouth in the 1960s, who reported that the ingestion of 150mg of aspirin substantially reduced the aggregation of platelets [1]. On the basis of this finding, and the assumption that the incidence of thrombosis would be reduced, O’Brien persuaded the UK Medical Research Council in 1968 to set up a randomised trial of aspirin [2].

Aspirin and Vascular Disease| Aspirin and the Prevention of Cancer| Aspirin and Bleeding| Further Research| Conclusion| References|